Axsome Therapeutics (AXSM) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Strategic focus and growth trajectory

• Maintains a core focus on CNS disorders, with openness to synergistic opportunities outside neuroscience if strategically justified.

• Employee count has grown from under 100 to over 1,000 in five years, reflecting rapid scaling.

• Projects significant evolution by 2031, driven by a robust pipeline and expanding indications.

• Ownership mentality and data-driven investment guide long-term strategy.

Product portfolio and recent approvals

• Three marketed products: AUVELITY (recently approved for Alzheimer's disease agitation), SYMBRAVO (migraine), and SUNOSI (excessive daytime sleepiness in OSA and narcolepsy).

• AUVELITY's differentiated mechanism and strong efficacy/safety profile support its use in both MDD and ADA.

• AUVELITY label highlights rapid onset, durable effect, and minimal adverse reactions.

• Peak sales guidance for AUVELITY raised to $8 billion, driven by label advantages, market share growth, and payer coverage.

Commercial strategy and market access

• Sales force expanded from 160 to over 600 reps, enabling deeper and more frequent HCP engagement.

• Commercial launch for ADA is on track, with sales reps trained to detail both MDD and ADA.

• Market access strategy aims for unrestricted coverage; current payer coverage at 86% of total lives.

• Long-term care facilities targeted for the first time, leveraging synergies between MDD and ADA.